-
People's Financial News|Dizal Pharma: Dizal's Self-Developed ZEGFROVY® (Sunvozertinib) Receives U.S. FDA Accelerated Approval for Market Launch
-
YICAI|The First Batch of Sci-Tech Innovation Bond ETFs Approved, with Net Inflows of RMB 172 Billion in Bond ETFs in the First Half of 2025
-
Shanghai Securities News|First IPO Approved under the Resumed SSE STAR Market's Fifth Set of Standards: Healthgen Biotechnology's IPO Approved by the Listing Review Committee
-
Xinhua|China grants 3.08 bln USD QDII quota in financial opening move
-
YICAI|China's Factory Activity Edges Up for Second Straight Month in June as US Trade Tensions Thaw
-
Global Times|HK's status as global financial center enhanced over 28 years
-
Securities Times|Wang Bo, Deputy General Manager of the Shanghai Stock Exchange: The SSE Will Vigorously Promote the Implementation of the SSE STAR Market's "1+6" Reform Measures and Demonstration Cases
-
Xinhua|Interview: Global professional services firm sees remarkable shift in China's corporate landscape
-
Xinhua|China, Europe look to strengthen cooperation on ESG promotion
-
YICAI|Chinese AI Chip Firms MetaX, Moore Threads See IPO Plans Move Forward
-
YICAI|China's Private VC Firms Launch Landmark USD186 Million Tech Bond Offering
-
China Daily|China issues guidelines on financial support to boost consumer spending
-
Shanghai Securities News|Broad-Based Index Products See Accelerated Expansion as Multiple SSE 380 and SSE 580 ETFs and Feeder Funds Are Filed